Shandong New Time Pharmaceutical Co., LTD clinical trials

A subsidiary of Lunan Pharmaceutical Group

The registry lists 35 studies whose lead sponsor is Shandong New Time Pharmaceutical Co., LTD. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 35 of 35. All Lunan Pharmaceutical Group studies →

• F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus ErythematosusRecruitingNCT07829614Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)RecruitingNCT07761429Phase 2/3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase I Clinical Study of LNF2105 in Patients With Advanced Solid TumorsNot yet recruitingNCT07661797Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07579234Phase 3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07312188Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 DiabetesNot yet recruitingNCT07046273Phase 3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and AdolescentsEnrolling by invitationNCT06863987Phase 3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute UrticariaRecruitingNCT06819774Phase 3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal DysfunctionRecruitingNCT06782594Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer BleedingNot yet recruitingNCT06783257Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerEnrolling by invitationNCT06755515Phase 2/3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid TumorsNot yet recruitingNCT06752447Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral NeuropathyNot yet recruitingNCT06722950Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase I Study of LNF1901 in Advanced Malignant TumorsNot yet recruitingNCT06226363Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase I Study of XZ120 in Malignant TumorsNot yet recruitingNCT06206915Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaRecruitingNCT05408221Phase 2/3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in HumansCompletedNCT07492173Not applicable

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in HumansCompletedNCT07478133Not applicable

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting ConditionsCompletedNCT07396506Not applicable

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Bioequivalence Study of Dronedarone Hydrochloride TabletsCompletedNCT07396519Not applicable

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase Ⅱ Study of F520 in Patients With Cervical CarcinomaCompletedNCT06226350Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty LiverCompletedNCT06202456Phase 4

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase IV Study of Huazhi Rougan GranuleCompletedNCT06188611Phase 4

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05741021Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsStatus unknownNCT05740215Phase 1/2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With OsteoporosisStatus unknownNCT05305183Phase 3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Study of F527 in Patients With Relapsed or Refractory LymphomaStatus unknownNCT05293028Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLStatus unknownNCT05178836Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mgCompletedNCT05076474Not applicable

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsStatus unknownNCT05040906Phase 3

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04984434Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Phase Ⅱ Study of F520 in Patients With Urothelial CarcinomaStatus unknownNCT04636515Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Status unknownNCT04457830Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)Status unknownNCT04457869Phase 2

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD

• Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520Status unknownNCT03657381Phase 1

  Sponsor listed in the registry: Shandong New Time Pharmaceutical Co., LTD